Effect of Compound Lactic Acid Bacteria Capsules on the Small Intestinal Bacterial Overgrowth in Patients with Depression and Diabetes: A Blinded Randomized Controlled Clinical Trial

Abstract

Objective. The objective is to explore the clinical effect of compound lactic acid bacteria capsules on the small intestinal bacterial overgrowth (SIBO) in patients with depression and diabetes. Methods. From January 2020 to January 2021, 60 SIBO patients with depression and diabetes in our hospital were selected and randomized into observation group (compound lactic acid bacteria capsules combined with escitalopram) and control group (Escitalopram) according to the odd and even numbers, 30 cases in each group. The two groups were compared in terms of SAS, SDS, levels of inflammatory factors, immune function, fasting plasma glucose (FPG), treatment effect, and the incidence of adverse reactions. Results. Both self-rating anxiety scale (SAS) and self-rating depression scale (SDS) scores in both groups showed a decline after treatment ( P < 0.05 ), and the reduction was more significant in the observation group ( t = 10.047 , 17.862, all P ≤ 0.001 ). Both IL-2 and TNF-α in both groups showed a decline after treatment ( P < 0.05 ), and the reduction was more greater in the observation group in relative to the control group ( P < 0.05 ). CD3+ and CD+4 in both groups showed an increase after treatment ( P < 0.05 ), and the increase was more greater in the observation group as compared to the control group ( P < 0.05 ). After treatment, the FPG levels of patients in both groups showed a decline ( P < 0.05 ), and the reduction of FPG levels was more significant in the observation group than that in the control group ( t = 3.948 , P ≤ 0.001 ). The control group experienced a remarkably higher incidence of adverse reactions. Conclusion. The compound lactic acid bacteria capsule is a boon for SIBO patients with depression and diabetes. It can mitigate depression symptoms, improve immune function, reduce the level of inflammatory factors, and lower the FPG levels, along with fewer adverse reactions and robust effects.

Interactions of Antidepressant Escitalopram With Acetic Acid and Lactic Acid: DFT and Molecular Docking Analyses

“…It indicates that the associations of AA and LA with the drug ESCI might enhance their antidepressant-like action. In addition, these results agree with existing experimental results [23,24]. Further, the ESCI…AA interaction is found theoretically to be performing better than the drug ESCI alone and ESCI…LA couple docked in 6HIS.…”

“…The results were in support of the beneficial anti-inflammatory and anti-oxidant effects of ESCI in ulcerative colitis regardless of depressive conditions. Further, in 2022, the effect of the LA bacteria capsules on small intestinal bacterial overgrowth in patients with depression and diabetes was explored [24]. The results of this study used ESCI for depression states suggested that the compound LA bacteria capsule is a boon for patients of small intestinal bacterial overgrowth with depression and diabetes and can improve immune function and ease depression symptoms and reduce fasting plasma glucose and level of inflammatory factors.…”

Small Intestinal Bacterial Overgrowth (SIBO) and Twelve Groups of Diseases Related- Current State of Knowledge

“…When the intestinal microecology is out of balance, it will lead to aggravation of anxiety and depression symptoms, which counteracts on the gastrointestinal tract, causing microbiota imbalance, among which SIBO is the most common type. Consequently, it is particularly important to find a reliable and safe treatment for SIBO combined with depression [197].…”

A Comprehensive Review of Bioactive Compounds from Lactic Acid Bacteria: Potential Functions as Functional Food in Dietetics and the Food Industry

“…LAB, including Lactobacillus and Streptococcus lactis, have shown a positive effect in terms of improving the immunity of individuals. Wei et al [108] explored the clinical effect of compound LAB capsules with Escitalopram (a medicine used to treat depression) on small intestinal bacterial overgrowth (SIBO) in patients with depression and diabetes. CD 3+ and CD +4 showed a greater increment among individuals supplemented with LAB compared to the control.…”